The folate receptor as a rational therapeutic target for personalized cancer treatment
Conventional cancer treatment modalities have several limitations including lack of sufficient efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In contrast, targeted imaging agents can identify patients with receptors overexpressed on the surface of cancer cells, thus allowing appropriate selection of patients for personalized treatment with a desirable targeted therapeutic. The folate receptor (FR) has been identified as a new molecularly targeted entity, which is highly overexpressed on the surface of a spectrum of solid tumor cells, including ovarian, kidney, lung, brain, endometrial, colorectal, pancreatic, gastric, prostate, testicular, bladder, head and neck, breast, and non–small cell lung cancer.
Source: Drug Resistance Updates - Category: Drugs & Pharmacology Authors: Yehuda G. Assaraf, Christopher P. Leamon, Joseph Reddy Source Type: research
More News: Bladder Cancer | Brain | Brain Cancers | Cancer | Cancer & Oncology | Colorectal Cancer | Drugs & Pharmacology | Endometrial Cancer | Gastric (Stomach) Cancer | Gastroenterology | Lung Cancer | Neurology | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Toxicology | Urology & Nephrology